AEGIRBIO AB
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as AegirBio … Read more
AEGIRBIO AB (52Q) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AEGIRBIO AB (52Q) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AEGIRBIO AB - Net Assets Trend (None–None)
This chart illustrates how AEGIRBIO AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AEGIRBIO AB (None–None)
The table below shows the annual net assets of AEGIRBIO AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AEGIRBIO AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AEGIRBIO AB Competitors by Market Cap
The table below lists competitors of AEGIRBIO AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACHETER-LOUER EO 145612
F:2ZT
|
$1.36K |
|
Scepter Holdings Inc
PINK:BRZL
|
$1.36K |
|
Blanco Y Negro
SN:COLOCOLO
|
$1.36K |
|
Bow Street Group plc
LSE:BOW
|
$1.36K |
|
Rescap Liquidating Trust
PINK:RESCU
|
$1.36K |
|
StoneBridge Acquisition II Corporation Rights
NASDAQ:APACR
|
$1.36K |
|
BIOALLIANCE PHARMA
MU:C4X
|
$1.35K |
|
Teejay Lanka PLC
CM:TJLN0000
|
$1.35K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AEGIRBIO AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AEGIRBIO AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AEGIRBIO AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AEGIRBIO AB's net assets metrics with peer companies in the Software - Infrastructure industry.
Industry Context
- Industry: Software - Infrastructure
- Average net assets among peers: $3,041,068,842,467
- Average return on equity (ROE) among peers: 9.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AEGIRBIO AB (52Q) | €- | N/A | N/A | $1.36K |
| ADYEN N.V. EO-01 (1N8) | $868.32 Million | 26.98% | 2.00x | $26.45 Billion |
| Endava plc (2Y5) | $639.46 Million | 2.68% | 0.59x | $150.99 Million |
| 3QG0 (3QG0) | $792.78K | -57.41% | 0.26x | $1.33K |
| EML Payments Ltd (A8Y1) | $119.21 Million | 0.07% | 0.26x | $105.37 Million |
| Amdocs Limited (AOS) | $3.41 Billion | 13.10% | 0.56x | $6.26 Billion |
| Circus SE (CA1) | $3.00 Million | -506.96% | 5.53x | $93.85 Million |
| PT GoTo Gojek Tokopedia Tbk (CK8) | $30.40 Trillion | -16.95% | 0.42x | $2.10 Billion |
| Cyan AG (CYR) | $219.31K | 629.46% | 12.30x | $23.39 Million |
| Intellistake Technologies Corp. (E41) | $-1.62 Million | 0.00% | 0.00x | $57.79 Million |
| Enea AB (publ) (EED5) | $1.85 Billion | 7.73% | 0.37x | $65.43 Million |